FDA rejects Eagle Pharmaceuticals’ heat stroke treatment

July 26 (Reuters) – Eagle Pharmaceuticals Inc saidon Tuesday the U.S. Food and Drug Administration declined toapprove its drug Ryanodex to treat heat stroke and requested anadditional clinical trial.
The post FDA rejects Eagle Pharmaceuticals’ heat stroke treatment appeared first on RocketNews | Top News Stories From Around the Globe.